Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	512.27M	124.39M	114.49M	139.16M	134.22M	121.98M	114.80M	117.55M	119.84M
Cost of Goods Sold	180.81M	38.12M	33.74M	50.35M	58.60M	54.76M	53.70M	54.22M	60.18M
Gross Profit	331.47M	86.28M	80.75M	88.82M	75.63M	67.23M	61.10M	63.33M	59.66M
Gross Profit Margin	64.7%	69.4%	70.5%	63.8%	56.3%	55.1%	53.2%	53.9%	49.8%
Total Operating Expenses	114.91M	33.83M	30.40M	26.07M	24.61M	24.43M	26.22M	25.01M	20.02M
Research & Development	11.52M	6.01M	2.60M	1.38M	1.53M	1.03M	826K	391K	412K
Selling, General & Administrative	100.04M	26.74M	26.74M	23.51M	23.05M	22.21M	24.08M	23.32M	18.56M
Operating Income (EBIT)	216.50M	52.45M	50.29M	62.75M	51.01M	42.80M	34.88M	38.32M	39.64M
Operating Margin	42.3%	42.2%	43.9%	45.1%	38.0%	35.1%	30.4%	32.6%	33.1%
Income Before Tax (EBT)	216.47M	50.24M	57.13M	61.59M	47.52M	40.10M	33.45M	34.71M	36.75M
Interest Income	3.19M	1.24M	1.09M	487K	376K	400K	608K	598K	666K
Interest Expense	8.82M	3.42M	2.10M	1.63M	1.68M	1.83M	1.98M	2.88M	3.50M
Other Income/Expense	-28K	-2.21M	6.83M	-1.16M	-3.50M	-2.70M	-1.43M	-3.61M	-2.89M
Net Income	168.96M	37.82M	45.33M	49.38M	36.43M	34.22M	26.90M	111.90M	35.91M
Income Tax Expense	47.52M	12.41M	11.80M	12.22M	11.09M	5.88M	6.55M	-77.18M	840K
Net Profit Margin	33.0%	30.4%	39.6%	35.5%	27.1%	28.1%	23.4%	95.2%	30.0%
EBITDA	226.03M	56.06M	52.13M	64.80M	53.03M	44.86M	36.85M	40.27M	41.58M
EBITDA Margin	44.1%	45.1%	45.5%	46.6%	39.5%	36.8%	32.1%	34.3%	34.7%
Depreciation & Amortization	9.53M	3.62M	1.84M	2.05M	2.02M	2.06M	1.97M	1.94M	1.94M
EPS Basic	0.72	0.17	0.19	0.21	0.15	0.14	0.11	0.47	0.15
EPS Diluted	0.70	0.16	0.19	0.20	0.15	0.14	0.11	0.46	0.15
Weighted Average Basic Shares	228.23M	228.23M	236.07M	237.97M	238.60M	241.49M	237.78M	236.43M	234.57M
Weighted Average Diluted Shares	230.34M	230.34M	239.96M	243.85M	244.66M	248.61M	244.68M	245.90M	244.80M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	510.17M	426.45M	258.21M	154.08M	80.94M	42.22M	29.35M	16.99M
Cost of Goods Sold	217.41M	206.90M	169.27M	118.81M	79.77M	61.29M	39.50M	42.19M
Gross Profit	292.76M	219.55M	88.94M	35.27M	1.17M	-19.07M	-10.16M	-25.21M
Gross Profit Margin	57.4%	51.5%	34.4%	22.9%	1.4%	-45.2%	-34.6%	-148.4%
Total Operating Expenses	101.32M	80.57M	67.31M	74.63M	59.55M	45.84M	31.27M	35.08M
Research & Development	4.76M	1.81M	3.30M	3.61M	3.65M	5.91M	2.34M	3.93M
Selling, General & Administrative	91.58M	74.12M	59.02M	52.46M	42.90M	35.05M	25.91M	22.50M
Operating Income (EBIT)	191.44M	138.98M	21.63M	-39.37M	-58.37M	-64.91M	-41.42M	-60.29M
Operating Margin	37.5%	32.6%	8.4%	-25.5%	-72.1%	-153.8%	-141.1%	-354.9%
Income Before Tax (EBT)	182.66M	125.71M	-28.24M	-65.90M	-71.65M	-75.75M	-48.28M	-65.74M
Interest Income	1.87M	2.10M	1.62M	45K	35K	288K	801K	195K
Interest Expense	7.11M	13.93M	25.03M	19.28M	13.06M	11.99M	8.99M	5.52M
Other Income/Expense	-8.79M	-13.27M	-49.87M	-26.54M	-13.27M	-10.83M	-6.85M	-5.45M
Net Income	146.93M	197.67M	-28.24M	-65.90M	-71.65M	-75.75M	-48.28M	-65.74M
Income Tax Expense	35.73M	-71.96M	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	28.8%	46.4%	-10.9%	-42.8%	-88.5%	-179.4%	-164.5%	-387.1%
EBITDA	199.54M	147.03M	29.96M	-32.25M	-52.88M	-60.97M	-38.17M	-56.84M
EBITDA Margin	39.1%	34.5%	11.6%	-20.9%	-65.3%	-144.4%	-130.0%	-334.7%
Depreciation & Amortization	8.10M	8.04M	8.33M	7.11M	5.50M	3.94M	3.26M	3.45M
EPS Basic	0.62	0.85	-0.13	-0.43	-0.61	-1.02	-1.05	-1.45
EPS Diluted	0.60	0.81	-0.13	-0.43	-0.61	-1.02	-1.05	-1.45
Weighted Average Basic Shares	238.30M	233.08M	223.98M	197.87M	139.58M	86.15M	54.35M	45.19M
Weighted Average Diluted Shares	244.90M	243.34M	223.98M	197.87M	139.58M	86.15M	54.35M	45.19M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About ADMA Biologics, Inc.

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

Ramsey, NJ

644 employees

www.admabiologics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Adam S. Grossman

View full financials